CYRX Overview

Cryoport, Inc. provides temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. The Company supports biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products. Its integrated supply chain platform includes the Cryoportal Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems. The Company's segments include Life Sciences Services and Life Sciences Products. The Company's Life Sciences Services segment provides cryogenic biostorage within the life science industry through direct sales. Its Life Sciences Products segment manufactures and sells cryogenic freezers, cryogenic dewars and accessories within the life science industry through direct sales or a distribution network.

Wall Street analysts forecast CYRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYRX is11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cryoport Inc revenue for the last quarter amounts to 45.45M USD, increased 9.64

Cryoport Inc. EPS for the last quarter amounts to -0.27 USD, decreased -35.71

Cryoport Inc (CYRX) has 684 emplpoyees as of March 21 2026.

Today CYRX has the market capitalization of 400.84M USD.